This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Chadi Alraies discusses some of the important trials presented at the European Society of Cardiology 2024 congress. For more cardiology research news join our newsletter or follow us on Twitter , Facebook , LinkedIn or Instagram. The post ESC 2024 Highlights appeared first on Cardiology Update.
Electrophysiological study will show that, and this pathway can be ablated. Ebstein’s anomaly may present with a murmur for evaluation in the pediatric age group or in adults with arrhythmias or heartfailure with cyanosis and exercise intolerance.
AF-CHF trial in those with AF and congestive heartfailure also failed to show any advantage for the rhythm control strategy [3]. Overall, it appears that rhythm control strategy in AF may be better in those with heartfailure and in those with associated cardiovascular conditions and early AF.
Chadi Alraies discusses the top impactful trials presented at the 2024 American College of Cardiology conference. For more cardiology research news join our newsletter or follow us on Twitter , Facebook , LinkedIn or Instagram. The post ACC 2024 Highlights appeared first on Cardiology Update.
Chadi Alraies discusses highlights from the American Heart Association (AHA) Scientific Sessions 2023, which were held in Philadelphia, Pennsylvania (PA), on November 11-13, 2023. There were many important developments in presented in key clinical trial presentations and publications stemming from the AHA Scientific Sessions 2023.
Investigators assessed if empagliflozin could lower the risk of hospitalization for heartfailure (HF) or death from cardiovascular disease (CVD). EMPACT-MI 1 ( NCT04509674 ) studied the effects of empagliflozin in patients who have experienced myocardial infarction (MI).
For more cardiology research news join our newsletter or follow us on Twitter , Facebook , LinkedIn or Instagram. The post TCT 2023 Highlights appeared first on Cardiology Update. Dr. Chadi Alraies provides an overview of the top highlights from TCT 2023.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content